Omnicell’s (NASDAQ:OMCL) Q2 CY2026: Beats On Revenue But Stock Drops On Weak Guidance
Omnicell (NASDAQ:OMCL) reported Q2 CY2026 revenue of $312.2 million, up 7.4% year on year and 0.6% above Wall Street estimates, and non-GAAP EPS of $0.94, above consensus. For next quarter, it guided revenue to $304 million, below estimates, and guided weaker EPS. The stock fell 5.6% to $39.08.
How this was made
The 30-second read
Why it matters
Traders likely reprice the stock around the guidance gap: despite a Q2 beat, the next-quarter revenue outlook is below consensus, and the stock sold off 5.6% immediately after results.
Market read
A mixed quarter with a guidance-driven selloff: EPS and revenue beat, but next-quarter revenue guidance underperforms consensus.
What to watch
The article notes product segment outperformance and a sharp adjusted operating margin improvement, which may offset the revenue guide if investors extrapolate margins more than top-line.
Background
Omnicell provides medication management automation and adherence tools, targeting an “Autonomous Pharmacy” model to reduce medication errors.
Ticker impact
Omnicell beat Q2 revenue and adjusted EPS, but guided next-quarter revenue to $304M, below estimates, and shares fell 5.6% to $39.08.
Choppy to bearish near term, with follow-through risk if investors focus on the below-consensus revenue guide rather than the EPS beat.
The article cites a revenue beat and EPS beat, yet the key incremental catalyst is the next-quarter revenue guidance coming in below analysts’ estimates, coinciding with a same-day stock drop.
Market effects
Signals healthcare automation demand may be uneven, with investors rewarding margin expansion but penalizing revenue visibility.
No specific regional spillover mentioned.
No global macro or cross-border catalyst mentioned.
Counterpoint
Margin and adjusted EPS strength could indicate operating leverage, so the guidance miss may be temporary rather than a structural demand slowdown.
Key entities
- companyOmnicell
Healthcare tech company reporting Q2 CY2026 results and issuing next-quarter revenue guidance.
- market_referenceWall Street estimates
Analyst consensus figures used to frame the beat/miss on revenue and guidance.
